<DOC>
	<DOCNO>NCT00837330</DOCNO>
	<brief_summary>This Phase I/II safety study design investigate safety efficacy ranibizumab ( Lucentis ) treatment polypoidal choroidal vasculopathy ( PCV ) , potentially blind eye disease involve growth tiny , abnormal blood vessel retina . These abnormal blood vessel bleed leak fluid , cause disruption normal retinal function vision loss . Ranibizumab drug FDA-approved treatment wet age-related macular degeneration ( AMD ) inject directly eye . Given efficacy ranibizumab treatment wet AMD , postulate similarity disease mechanism involve wet AMD PCV , believe ranibizumab beneficial effect visual function patient PCV .</brief_summary>
	<brief_title>Ranibizumab ( Lucentis ) Polypoidal Choroidal Vasculopathy</brief_title>
	<detailed_description>Please see description . Phase I/II safety study ; prospective , open-label , single-center , non-randomized , uncontrolled , consecutive interventional case series . Enrolled patient &gt; 35 year old display exudative , active polypoidal choroidal vasculopathy ( PCV ) 1 eye . PCV define choroidal neovascularization display occult characteristic fluorescein angiography polypoidal interconnect vascular channel saccular dilatation indocyanine green angiography and/or fluorescein angiography . Eyes receive 3 consecutive , monthly intravitreal ranibizumab injection ( 0.5 mg 0.3 mg/0.05 cc ) follow monthly evaluation option additional intravitreal ranibizumab alternative treatment discretion investigator . Baseline follow-up evaluation include medical history , blood pressure , physical examination , early treatment diabetic rentinopathy study ( ETDRS ) best-corrected visual acuity ( BCVA ) , intraocular pressure measurement , complete ophthalmologic examination , fundus photography , fluorescein/ indocyanine green ( ICG ) angiography , optical coherence tomography ( OCT ) .</detailed_description>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Age &gt; 35 year Exudative , active PCV 1 eye . PCV define choroidal neovascularization display occult characteristic fluorescein angiography polypoidal interconnect vascular channel saccular dilatation indocyanine green angiography and/or fluorescein angiography . Age &lt; 35 year Prior treatment nonranibizumab therapy ( e.g. , laser , surgery , bevacizumab )</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>polypoidal choroidal vasculopathy</keyword>
	<keyword>choroidal neovascularization</keyword>
	<keyword>ranibizumab</keyword>
	<keyword>Lucentis</keyword>
</DOC>